MetaCap

Mineralys Therapeutics (MLYS) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ocular Therapeutix (OCUL) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 54.5% versus a loss of 67.4%. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLYS-67.38%OCUL-54.49%
+37%-18%-72%
Nov 21, 20251 yearNov 20, 2026
MLYS-25.92%OCUL+43.93%
+293%+105%-83%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLYS versus OCUL key metrics
MetricMLYSOCUL
Share price$13.66$5.57
Market cap$1.21B$1.23B
1-day change-3.53%-4.95%
YTD return-62.36%-54.12%
1-year return-67.38%-54.49%
5-year return—-14.83%
EPS (TTM)$-4.30$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$51.95M
Revenue growth (YoY)—-18.47%
Net income (latest FY)$-154.65M$-265.94M
Gross margin—87.35%
Operating margin—-519.75%
Net margin—-511.90%
52-week high$44.13$16.44
52-week low$13.57$5.54
Distance from 52-week high-69.05%-66.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.89%+361.94%
Average volume1.55M3.03M
Shares outstanding88.56M220.02M
Employees76325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OCUL has outperformed MLYS by 12.9 percentage points over the past year.

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

MLYS vs OCUL FAQ

Which is bigger, Mineralys Therapeutics or Ocular Therapeutix?

Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.21B for Mineralys Therapeutics (MLYS).

Which stock has performed better over the past year, MLYS or OCUL?

OCUL returned -54.49% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are Mineralys Therapeutics and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons